12:25 PM EDT, 03/12/2025 (MT Newswires) -- GSK's (GSK) majority-owned Viiv Healthcare said Wednesday the phase 2b study found that N6LS antiviral kept viral levels suppressed in adults with HIV, when given in combination with cabotegravir long-acting.

In the study, N6LS was given every four months along with monthly cabotegravir long-acting to patients already stable on treatment. The antiviral was also well tolerated by the participants, the company said.

At the six-month primary endpoint, the study showed that 96% of participants receiving N6LS intravenously and 88% receiving it subcutaneously with rHuPH20 maintained HIV-1 RNA levels below 50 copies per milliliter, compared to 96% in the standard-of-care group, the company said.

ViiV Healthcare plans to progress a six-month intravenous formulation of the candidate in combination with cabotegravir long-acting for further evaluation in part two of the trial.

Pfizer ( PFE ) and Shionogi are also shareholders in Viiv Healthcare.

Price: 39.08, Change: -0.42, Percent Change: -1.06